3 . Tedros Ghebreyesus
@DrTedros
1. Empathy
2. Approachability
3. Hardwork- roll up the sleeves and leading from the front
4. Conciliatory
5. Standing up for the underprivileged nations
Delighted to see 🇬🇧 PANTS study 3 year extension data published in
@LancetGastroHep
🙏🏼 to the investigators and patients who participated
⏺️Only 1/3 of those treated with TNFis remain in remission at 3years
⏺️Week 14 levels significant in reducing
📣📣📣📣📣💥💥💥💥
Truly transformational work by
@Dr_James_Lee
and
@TheCrick
team 👇
Macrophages driving IBD origin ; and perhaps also other autoimmune disorders
HUGE potential 👀
IF this information about GI bleeding rota is FACTUALLY CORRECT , it will be of serious concern in my opinion
@BritSocGastro
@JAG_Endoscopy
I am somewhat surprised as this hospital has excellent gastroenterologists & clinicians providing excellent GI care and also
I always suspected this was the case somewhere in the UK…
A Physician Associate doing GI bleed endoscopy‼️
As a Consultant, GI bleed endoscopy can be the most challenging work we do
I can categorically say this is unsafe & unacceptable from a patient safety PoV.
#Frightening
No second chance for monotherapy for anti TNF. The use of Aza a MUST if using a second anti TNF following secondary LOR with anti TNF monotherapy. RCT from the
#LaurentPB
and team .
Adalimumab: A ‘Maillon Faible’ in the Treatment of UC
👇the 🔨 on the ⚰️ of
#Ada
for
#UC
.
Never used
#Ada
in
#UC
& was criticised for many yrs .
Lesson for future : when evaluating new
#MoAs
don’t always expect similar efficacy in UC & CD
🔥 hot of press in
@Gut_BMJ
First
@clarityibd
results
✳️ n= 6️⃣9️⃣3️⃣5️⃣
9️⃣2️⃣ 🇬🇧 🏥
🧐 impact of biologic class+/IMM on anti-SARS-CoV-2 seroconversion
🔎TNFi vs Vedo
🚨⬇️seroprevalence
🚨⬇️seroconversion
🚨⬇️anti-SARS-CoV-2 reactivity
🚨Further ⬇️with combo with AZA/MTX
Join me in congratulating Dr Sree Subramanian ( working on him to join twitter !) from
@RoyalLpoolHosps
who is the recipient of the prestigious
@NIHR
-
@RCPLondon
research award for the phenomenal work in printing research in Mersey
#GI
research.
#risingstar
💫
Back from
#ECCO2023
My main reflection
✅ECCO is on 🪜 to be truly global org
🙏🏾-humbled to meet &make some new 🙌from 🇧🇷 🇨🇱 🇧🇴 🇦🇷 🇵🇪 🇺🇾 🇨🇴 🇸🇻 🇨🇷 🇲🇽 🇿🇦 🇸🇩 🇪🇹 🇩🇿 🇪🇬 🇸🇦 🇮🇷
✅LOT more to do in the 🌎 vision - 👀 forward to 🙌💪🏿 our current & next president on shared goals 👇
#IBD
is 📈 a Global 🌎 problem
❗️Evolving epidemiology trends
❗️
#LLMIC
WILL be the new frontiers
⏯️🌎 Global problems need 🌎 Global solutions through 🧐 🔬
⏯️Research in
#IBD
should be Global 🌎
But is it really global 🌎 now ??
@LancetGastroHep
SR in collaboration
This 👇is incredible .
Wonder 💭 when we will ever reach this stage for
#IBD
🤔
Great hope to identify the causes of IBD by 🌎 research 🤞
Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis | Nature Medicine
Introductory meeting of the participants of of the
#ECCO
consensus project meeting on
#IBD
in lower and lower middle income countries
Led by
@AlaaEl_Hussuna
First of many steps by
#ECCO
leading
#IBD
care , research and education to tackle global 🌎 challenges in
#IBD
🔥off the 🗞 .
Delighted to share 🇬🇧 study
#PROTECTASUC
@LancetGastroHep
🛑Dual challenge in
#IBD
#ASUC
: Need 🏥 Tx, High dose steroids
& 🦠:
🤔🧨 high dose steroids, immunosupp ,disease activity.
Mx and outcomes 👇- overall reassuring ❇️
📣 💥
Opportunity to be the next
#IBD
fellow to join our team at
@IbdHull
to horne your skills in complex
#IBD
management and develop research 🔬🧐 skills
Friendly integrated clinical and research
#IBD
team
👇
DMs open. Please retweet 🙏🏼
World IBD day 2024
An opportunity to reaffirm our commitment to global 🌍
#IBD
care and global 🌎 collaborative research
🧑🧑🧒🧒 C -A -R -E principles 👇
📶 R - E - A- C - H from
#ECCO
📢 📣
#ECCO
family
Rapid pace of dev. for
#AI
in
#IBD
.
Honoured to co-ordinate the 9th
#ECCO
Scientific Workshop with
@IBD_MB
🙏🏼 to all applicants . Was really difficult to choose .
✅ successful applicants received comms today from
#ECCO
⏺️ 🙏🏼the working group leads
This is an important moment for ECCO - truly global 🌎 organisation
Gill Watermeyer
@ibd_africa
with
#ECCO2023
lecture
Sobering data of challenges 🥲
Really concerning re: brain drain - we should & can do better
@BritSocGastro
Absolutely fascinating data from GEM Project on environmental influences in
#CD
@guthealthmd
Early exposure to pets and impact of microbiome and barrier function 🤔
We all need to get a 🐶 🐕 !!
Delighted to have completed the
#VirtualRunforGuts
. Ok snail 🐌 pace but took in the local scenery on the way. 🙏 to all those who dipped into their pockets to support this small contribution led by
@GastroMJB
. Thank you
@CrohnsColitisUK
and
@GutsCharityUK
for all what you do
Alternate day versus daily oral iron for treatment of iron deficiency anemia: a randomized controlled trial | Scientific Reports
Another nail in the ⚰️for the overuse of oral iron in IDA
Nice study from 🇮🇳 by
@basheeraneesh
@UKGastroDr
Hi
@British_Airways
Perhaps you should train your crew on equality , diversity so that covert racist behaviour is not experienced by your customers. Not asking for apology but please attempt to change end
Tim Raine
@IBD_MB
with results of 🇬🇧
#IASO
trial of Anakinra (IL-1 antagonist) in
#ASUC
⏺️ negative study
Key 🔑: it is feasible to do RCT in
#ASUC
and we will need to move the 🪡 in this challenging complication
#ECCO24
De Willebois et al
The SPICY Trial .
Extended Mesenteric resection
Vs
Mesenteric sparing
NO difference
Message: uncontrolled data not translated into RCT evidence
@charlie_lees
#DDW2023
First data from
@predicct
study from 🇬🇧
Meat 🥩 intake seems to increase risk of flares
But no impact with Fibre and PUFAs and UPFs 🤔
Massive 🙏 to our
@HullHospitals
CEO Chris Long and chief nurse
@Bgearyyork
for inaugurating our new immunomodulatory infusion centre (IMIC) for
@IbdHull
. 🙏 for spending time time with our patient panel reps and
#IBD
team.🙏for offer to support us in our vision
#excellence
The integrated
#IBD
team
@HullHospitals
10 years old and now reaping the benefits of the model ▶️ better patient outcomes 👀data soon .
🙏our research active patients
🙏the excellent leadership from
@EmmaIBDhull
&
@salhullibd
🙏
@IbdHull
team.
#worldibdday2021
.
We
@IbdHull
hope we can continue to deliver the best possible care to our
#IBD
pts via
#integratedcare
Massive 🙏 to our
#IBD
patients for their
❇️ resilience & ❇️patience through a challenging period
and for
❇️ for supporting our research.
1/2
International Fistula Consortium meeting
@DDWMeeting
#DDW2023
Trying to tackle this challenging area of
#CD
#UnmetNeed
👀 out for outputs from this multidisciplinary collaboration
Not sure 🤔 whether means anything at all but in 🏏 ing terms reached half century.
Thank you 🙏🏾 to research team, IBD fellows , collaborators and most importantly
#IBD
patients who participate in our 🔬🧐
👇
Massive thanks 🙏🏼
It was an absolute honour to return to my alma mater and to see so many familiar faces and some new faces
Humbled and stimulated by the quality and sheer volume of work being done
@gi_pgi
Highlights many to mention including seeing the person who taught me
Pleased to host Prof
@ibdseb
as a visiting professor to
#PGIMER
- a brilliant speaker and remarkable leader... Thank you for guiding us and inspiring our fellows.
#ECCO2021
@ryanungaro
showing what we suspected before
Mesalazine after all NOT associated with increased risk of severe
#COVID19
⏺Evolution of data
⏺Limitation of registry studies with convenience sampling
The IBD research landscape in the UK is rich and deep.
Many practice changing studies in various stages of development and dissemination.
Promises to be an invigorating
@BritSocGastro
day tomorrow in Exeter.
#ECCO24
Prof Subrata Ghosh - a brilliant 🗣️ on life style modifiers in
#IBD
The key 📣 :
Don’t jump into conclusions based on association studies even if they are large.
Work on 👇
Ruslan’s concepts of inflammation:
Loss of structure
Loss of function
Loss of control
I don’t usually comment on political matters but this is worth retweet 👉Respect standing up for the right think
👉How many people in positions of influence even in professional organisations are prepared to back a right message 🤔
Tough life ☺️
After a busy (but enjoyable ) day learning
#IBUS
chill time with some of the faculty and colleagues
🙏🏼
@novakkerri
@guthealthmd
for the hospitality
DOP44 Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID):
This study from 🇮🇳 is interesting (as well as sobering)
steroids = tofacitinib in induction of remission & response
#ECCO
topical review on peri operative care 👇Manuscript in full.
The main goal of this work is to 🚀 multidisciplinary care & 🧐 🔬 in periop care for
#IBD
among
▶️Physicians
▶️Surgeons
▶️IBD nurses
▶️Dieticians
▶️Psychologists
▶️Stoma therapists
New MOA of
@my_ueg
#UEGWeek2023
@SeverineVermei1
Obefazimod - a miR 124 based small molecule in
#UC
. Originally developed for an infection🤔
Relatively refractory population
2 year data looks good 👇
Dose optimisation for
#Vedo
in primary NR @ week 6 with high clearance doesn’t improve response rates
Clinically relevant results from ENTERPRET Trial
🔑 receptor occupancy ?
@AndresYarur
#DDW2022
Edouard Louis
#ECCO2023
Excellent lecture on a challenging area
❓Can we reverse fibrosis in
#IBD
❓Can we learn from hepatology
🔐 understand , identify and then unlock the pathways involved in fibrosis
Bispecific antibodies as a strategy for breaking therapeutic sealing in
#IBD
@Iris_Dotan
- brilliant futuristic lecture on an approach learning from oncology field .
Side effects will be the concern . Is this a runner ? 🤔
#ECCC2023
One of the most enjoyable and rewarding aspects when travelling for
#IBD
#MedEd
is meeting residents
Here
@YashodaHospital
discussing integrating research into daily clinical care in
#IBD
Hope I can inspire the residents.
I am truly inspired by incredible quality in India
#Vermeire
with results of LOVE-UC study
#DDW2021
❓Timing to use of Vedo based on disease duration
Early Vedo (<4 years, only 5ASA or steroids )
Vs
Late Vedo (>4 years and ongoing or prior use of IMMs or TNFi )
⏺ No difference in remission rates in Wk26 or Wk52
Delighted to share our paper in
@APandT
from
@ElevateAsuc
study group accelerated IFX induction in steroid refractory acute severe colitis.
@ElevateAsuc
prospective study with clinical,pharmacokinetic ,endoscopic and translational work packages on way
The New classification of pCD is a vital step progressing research in personal fistula in CD . Suggest all
#IBD
units use this .
The original paper
An analysis of the use of the
#TOPCLASS
classification 👇
#TOpCLASS
classification highlights the dynamic nature of perianal fistulizing
#CD
over time, however, our ability to predict transitions between classes remains limited and requires prospective assessment.
@MattSchro314
@P_DeepakIBDMD
@ibdseb
This 💯
In the clinical trials space for
#IBD
therapeutics , significant under representation & underreporting exists as we recently reported in
@LancetGastroHep
…👇
BUT : I do feel we are getting better
We need to do more
5 Keys 🔑 steps IMHO
Inflammatory Bowel Disease does not discriminate.
Tens of millions of people are affected across the world.
But they cannot expect the same care, the same access to therapies and monitoring tools.
Within countries with the same rules, the same drugs and the same healthcare
We are getting closer to understanding different
#IBD
phenotypes .
This 👇is a must ready from the incredible
@WeersmaLab
@BourgonjeArno
Mucosal host-microbe interactions associate with clinical phenotypes in
#IBD
|
👇This is part of
#ECCO
commitment to global 🌎 education& research 🧐 🔬
Looking forward to supporting
@AlaaEl_Hussuna
in this imp work
If you are an
#IBD
HCP in a LMIC country& passionate about progressing
#IBD
care across the 🌍 please do consider applying
#Equity
#IBD
@JeanFredericCo1
Emotion appears in Jean Frederick face as he is recognized as a great researcher, mentor and leader of
#IBD
family all over the world. 👍👍👍👏👏👏
#DDW2024
#Diet
in
#IBD
- still lot to understand but huge progress from the simple concepts of the past ie EEN
@LGodny
with an excellent talk at 🇮🇱 IBD Society meeting
Wow
Hugely impressed by the Quality of abstracts at
#ECCO2024
Many investigator initiated studies with potential to change
#IBD
practice- really tough to decide on the best ones for the
#ECCO
IIS awards
Do register to attend
#ECCO2024
in Stockholm
Happy
#WorldIBDDay
from the SAIA/
@ibdesis
team!
Today we join hands as patient advocates and healthcare providers to encourage our fellow
#IBD
family around the world to
#BreakTheSilence
& say
#GameOverIBD
!
Teamwork makes the dream work! Join us today in breaking the silence!